Learn how doggybone DNA (dbDNA™) vaccines offer a safe, scalable alternative to plasmid DNA for cancer immunotherapy, delivering strong immune responses without bacterial components. Download the full article to learn:…
This article explores the development of an optimized linear DNA vaccine for influenza using Touchlight’s dbDNA™ platform. By incorporating neuraminidase (NA) alongside haemagglutinin (HA) and leveraging DNA targeting sequences (DTS),…
This article explores how Touchlight’s enzymatically amplified linear dbDNA™ technology overcomes the limitations of traditional plasmid-based methods in lentiviral vector (LVV) manufacturing. By optimizing vector design and transfection conditions, the…
This article presents a comparative study between traditional plasmid DNA vaccines and novel enzymatically produced linear DNA constructs known as "Doggybones." These linear constructs, which exclude unnecessary bacterial elements, demonstrated…
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers…
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers…
The most effective way to end the COVID-19 pandemic is through the development of medical countermeasures to combat SARS-CoV-2 infection and disease. The rise of the variants has also illustrated…
Induced pluripotent stem cells (iPSCs) represent a transformative platform for regenerative medicine and cell therapy, but clinical success depends on safe and reliable reprogramming methods. This study reports the first…